NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 Combo

 Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology

• Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders
• Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders
• Data suggest abscopal effect in some patients (i.e., reduction in non-injected / non-irradiated lesions)
• To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)
• New readout could provide promising signals for NBTXR3 as a potential pillar of immunotherapy
• Following ASCO, Nanobiotix will host an investor event on Friday, June 11, 2021 at 8:00 am Eastern Time (14:00 Central European Time), to provide an in-depth review of the immunotherapy data with several key opinion leaders including study investigators (Register here)

https://www.streetinsider.com/Business+Wire/NANOBIOTIX+Reports+New+Data+for+Potential+First-in-Class+Radioenhancer+NBTXR3+in+Combination+With+Anti-PD-1+Showing+Local+or+Distant+Tumor+Regression+in+76.9%25+of+Evaluable+Patients+Regardless+of+Prior/18518508.html